Poly (adenosine diphosphate [ADP]–ribose) (PARP) inhibitors were the first approved cancer drugs that specifically targeted the DNA damage response in BRCA1/2 mutated breast and ovarian cancers. Here, BRCA1 is linked to ovarian cancer.